Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	11/2/2007 6:55:39 PM
	of 3044

Nancy Simonian, M.D., Chief Medical Officer, Clinical, Medical and Regulatory Affairs, hasn't sold her 368 shares. I don't even know if she has got any. But while checking at the company website who and what Ms Protopapas is, I also saw the bio of Ms Simonian. She does sound competent on the CCs, btw. In her earlier life she was employed by Biogen, where she was responsible for the clinical development of AVONEX® (Interferon beta-1a), Tysabri (natalizumab) and their oncology programs. Interesting to see that she was working on natalizumab. Maybe MLN0002 isn't a dead end after all. She should at least have a fair idea what she is up against after the Tysabri experiences at her previous employer. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next